Tech Company Financing Transactions
Aurenar Funding Round
Aurenar, based in Saint Louis, secured $5.7 million from American Heart Association and Solas Bioventures.
Transaction Overview
Company Name
Announced On
7/28/2026
Transaction Type
Venture Equity
Amount
$5,700,000
Round
Seed
Investors
American Heart Association (Lead Investor)
Solas Bioventures (Lead Investor)
Proceeds Purpose
The company intends to use the funds to fund continued advancement toward pivotal trials, including final device development, verification and validation (V&V) testing, and regulatory submissions to the U.S. FDA.
Company Information
Company Status
Private & Independent
Industry
Medical Devices & Instruments
Mailing Address
Undisclosed
Saint Louis, MO Undisclosed
USA
Saint Louis, MO Undisclosed
USA
Phone
Undisclosed
Website
Email Address
Overview
Aurenar is on path to achieve tremendous health and economic impact by addressing inflammation - the underlying cause of life-threatening and costly complications in the ICU. Our ear-worn device boosts the body's natural control of inflammation by activating a nerve located in the ear with imperceptible and non-invasive stimulation.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Eric Leuthardt
Chief Financial Officer
Ryan Kight
Chief Medical Officer
Anna Huguenard
Chief Operating Officer
Jesse Wheeler
Chief Technical Officer
Jenna Gorlewicz
Founder
Jeff Dunn
VP - Bus. Development
Deborah Barta
VP - Bus. Development
Jeff Caputo
Browse more venture capital transactions:
Prev: 7/28/2026: Mate venture capital transaction
Next: 7/28/2026: FireAI venture capital transaction
Share this article
Where The Data Comes From
We do our best to record all VC transactions involving tech companies. VC investment data records reported here come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs